Stock Details
GRFS is Grifols, S.A.'s stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 8.27$. Average daily volumn in 3 months 1.13M. Market cap 5.81B



Stock symbol : GRFS. Exchange : NasdaqGS. Currency : USD
Lastest price : 6.74$. Total volume : 1.06M. Market state REGULAR
Click reload if you want to check the lastest price on market!!!

Grifols, S.A. (GRFS)
Last Price
6.74$
Change
0.30
Volume
1.06M

Previous Close6.44
Open6.37
Day Range6.37-6.75
Bid6.70 x 1.1k
Ask6.71 x 1.2k
Volume1.06M
Average Volume1.13M
Market Cap5.81B
Beta0.19
52 Week Range5.82-15.25
Trailing P/E67.40
Foward P/E8.99
Dividend (Yield %)N/A
Ex-Dividend Date2021-06-03



Financial Details


According to Grifols, S.A.'s financial reports the company's revenue in 2021 were 4.93B an decrease(-20%) over the years 2020 revenue that were of 5.34B. In 2021 the company's total earnings were 182.8M while total earnings in 2020 were 618.55M(-70.55%).


Loading ...



Organization

Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting fa... ctors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuum–from prevention, screening, diagnosis, and prognosis to disease and treatment monitoring–to serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.

Market Cap:
5.81B
Revenue:
4.93B
Total Assets:
19.23B
Total Cash:
655.49M


News about "Grifols, S.A."

Grifols S.A. ADR

Source from : Wall Street Journal - 6 days ago

Víctor Grifols Roura Non-Executive Chairman Scranton Enterprises BV, Grifols SA, Instituto Grifols SA, Grifols USA, Inc., Arrahona Optimus SL Raimon Grifols Roura Joint Chief Executive Officer ...See details»


heres-our-rant-about-grifols-sa-grfs-image

Here’s Our Rant About Grifols S.A. (GRFS)

Source from : newsheater - 4 days ago

Grifols S.A. (NASDAQ:GRFS) went down by -8.32% from its latest closing price compared to the recent 1-year high of $15.36. The company’s stock price has collected -23.13% of loss in the last five ...See details»


grifols-appoints-executive-chairman-as-seeks-to-speed-recovery-image

Grifols Appoints Executive Chairman as Seeks to Speed Recovery

Source from : U.S. News & World Report - 1 days ago

Grifols appointed an executive chairman on Monday, as the Spanish pharmaceutical company strives to recover from a pandemic-related hit and a 49% drop in its shares so far this year. Steven F. Mayer, ...See details»


grifols-sa-nasdaqgrfs-given-consensus-recommendation-of-hold-by-brokerages-image

Grifols, S.A. (NASDAQ:GRFS) Given Consensus Recommendation of “Hold” by Brokerages

Source from : Defense World - 3 days ago

Grifols, S.A. (NASDAQ:GRFS – Get Rating) has received an average rating of “Hold” from the eight ratings firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock ...See details»


Victor Grifols Roura decides to retire as Chairperson; Grifols appoints private equity veteran Steven F. Mayer as Executive Chairperson

Source from : Yahoo Finance - 1 days ago

Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS) announced today changes to its leadership team, appointing Mr. Steven F. Mayer as Executive Chairperson while Mr. Victor Grifols Roura retired as ...See details»


Grifols S.A. (GRFS): The stock ticks all the boxes for top investors

Source from : investchronicle - 6 days ago

Let’s start up with the current stock price of Grifols S.A. (GRFS), which is $6.60 to be very precise. The Stock rose vividly during the last session to $6.845 after opening rate of $6.80 while the ...See details»


Grifols SA - ADR - Level III

Source from : U.S. News & World Report - 14 days ago

These S&P 500 dividend stocks each yield more than 6%.See details»


Grifols SA (GRFS) was upgraded to a Buy Rating at Kepler Capital

Source from : Business Insider - 6 days ago

Kepler Capital analyst Dariusz Ubik upgraded Grifols SA (GRFS - Research Report) to a Buy on September 26 and set a price target of EUR19.40. The companys shares closed yesterday at $6.60.See details»


Grifols enters into agreement with Canadian Blood Services to accelerate self-sufficiency in immunoglobulins for Canada

Source from : Benzinga.com - 27 days ago

Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this ...See details»


Grifols SA Pref (GRLSbn)

Source from : Investing - 8 days ago

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...See details»


s-the-company-reaffirms-business-plan-image

S&P cuts Grifols rating, while Fitch, Moody’s leave unchanged; the company reaffirms business plan

Source from : The Corner - 7 days ago

Bankinter | S&P has cut Grifols debt rating, while Moody's and Fitch leave theirs unchanged. The board issues a statement reaffirming business plan.See details»


Albumin Market Evolution Segmentation and Insight of Trends 2022 to 2027 with Top Countries Data

Source from : MarketWatch - 5 days ago

The global Albumin market size was valued at USD 7420.02 million in 2021 and is expected to expand at a CAGR of ...See details»


There's a reason you are not getting the best sleep

Source from : FOX 5 Atlanta - 14 days ago

ATLANTA - When it comes to sleeping, Dr. Chantale Branson, Assistant Professor of Neurology Morehouse School of Medicine, says we need to get on a routine, where we go to bed at the same time ...See details»


New Discovery Can Kill COVID With ‘Hugs’—but There’s a Catch

Source from : The Daily Beast - 9 days ago

But there’s a problem. It’s one thing to identify a molecule in an academic study. It’s another to create a drug based on that molecule. “Academia is not well suited to commercialize a ...See details»